Analysts Issue Forecasts for ESPR Q1 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, March 10th. HC Wainwright analyst J. Pantginis expects that the biopharmaceutical company will post earnings of ($0.08) per share for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.04) EPS, FY2026 earnings at $0.00 EPS, FY2027 earnings at $0.25 EPS and FY2028 earnings at $0.45 EPS.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.01). The company had revenue of $168.45 million for the quarter, compared to analysts’ expectations of $165.12 million.

A number of other research firms have also issued reports on ESPR. Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Thursday, January 22nd. Wall Street Zen downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. Citigroup reiterated a “market outperform” rating on shares of Esperion Therapeutics in a research note on Wednesday, November 12th. Finally, Needham & Company LLC upped their price target on Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.25.

Esperion Therapeutics Stock Performance

NASDAQ ESPR opened at $2.59 on Thursday. The firm’s fifty day moving average is $3.33 and its two-hundred day moving average is $3.14. Esperion Therapeutics has a one year low of $0.69 and a one year high of $4.18. The firm has a market cap of $619.17 million, a PE ratio of -15.24, a P/E/G ratio of 0.55 and a beta of 1.11.

Insider Activity

In related news, CFO Benjamin Halladay sold 7,337 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total transaction of $26,926.79. Following the completion of the transaction, the chief financial officer directly owned 467,525 shares of the company’s stock, valued at $1,715,816.75. This represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders have sold 15,543 shares of company stock worth $55,709 in the last quarter. Insiders own 1.70% of the company’s stock.

Hedge Funds Weigh In On Esperion Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. DHJJ Financial Advisors Ltd. raised its stake in shares of Esperion Therapeutics by 209.2% during the 3rd quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 6,380 shares in the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of Esperion Therapeutics in the fourth quarter valued at approximately $35,000. KFG Wealth Management LLC acquired a new position in Esperion Therapeutics during the fourth quarter worth $37,000. Cary Street Partners Financial LLC acquired a new position in Esperion Therapeutics during the fourth quarter worth $38,000. Finally, Larson Financial Group LLC purchased a new position in Esperion Therapeutics in the fourth quarter worth $39,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

More Esperion Therapeutics News

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Q4 revenue significantly beat estimates — Q4 revenue of $168.45M (+144% YoY) and FY25 total revenue of $403.1M (21% Y/Y) highlight strong top-line momentum and product growth (U.S. net product revenue +38% Y/Y). GlobeNewswire Release
• Positive Sentiment: Company announced an acquisition alongside results, which earlier sparked buying interest and was cited by retail-focused coverage as a near-term catalyst. MSN: Shares Rise After Revenue Tops Forecasts and Acquisition
• Positive Sentiment: HC Wainwright reiterated bullish stance (Buy) and published an EPS forecast for the coming quarter, signaling at least one broker remains constructive on growth/catalysts. MarketBeat: HC Wainwright Note
• Neutral Sentiment: Earnings call materials and transcripts are available and include management commentary on product uptake and upcoming catalysts; these will be parsed by investors for guidance and cadence of future launches. Yahoo Finance Transcript Seeking Alpha Transcript
• Neutral Sentiment: Reported short-interest data appears to show zero shares (likely a reporting anomaly) and should not materially change the current supply/demand picture. (No reliable short-interest signal in latest filings.)
• Negative Sentiment: EPS missed consensus by $0.01 — reported EPS $0.22 vs. $0.23 est. The small EPS miss, despite the revenue beat, is being viewed negatively by traders and was a primary driver of intraday selling pressure. Zacks: Q4 Earnings Lag
• Negative Sentiment: Market reaction: shares swung intraday (earlier pops after the acquisition/revenue beat, then declines as the EPS miss and mixed messaging landed); trading volume ran above averages, indicating active repositioning by investors. MarketBeat: Trading/Volume Summary

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.